Jordi Remón

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

Laura Mezquita, Édouard Auclin, Roberto Ferrara et al. · JAMA Oncology · 2018 · 951 citations · Full text

Life Sciences, Immunology, Oncology +17

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Roberto Ferrara, Laura Mezquita, Matthieu Texier et al. · JAMA Oncology · 2018 · 738 citations · Full text

Medicine, Oncology, Pharmacology +14

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

M.F. Mosele, C. Benedikt Westphalen, A Stenzinger et al. · Annals of Oncology · 2024 · 345 citations · Full text

Medicine, Oncology, Molecular Oncology +12

Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA

Jordi Remón, Caroline Caramella, Cécile Jovelet et al. · Annals of Oncology · 2017 · 164 citations

Medicine, Genetics, Oncology +12

Crizotinib-Resistant <i>ROS1</i> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <i>ROS1</i> - and <i>ALK</i> -Rearranged Lung Cancers

Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo et al. · Clinical Cancer Research · 2016 · 149 citations

Medicine, Oncology, Pharmacology +17